Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2024—Bio-Rad Laboratories announced it received My Green Lab certification for its R&D facilities in Irvine, Calif. It has been certified at My Green Lab’s highest rating, green, which reflects the percentage of possible green lab best practices that have been adopted and the extent to which they have been adopted by the lab.
April 2024—Recordati Rare Diseases has introduced its new educational website, thinkimcd.us. The platform is tailored for pathologists, offering comprehensive support for the diagnostic process of idiopathic multicentric Castleman disease (iMCD). The site provides an overview of iMCD diagnostic criteria, practical steps for assessing lymph node biopsies, and links to additional resources for understanding CD/iMCD. Designed to enhance professional awareness and comprehension, thinkimcd.us aims to be a valuable tool for the medical community.
April 2024—Siemens Healthineers now offers the Anti-Müllerian Hormone assay to evaluate ovarian reserve. The assay runs on the Atellica IM analyzer and Advia Centaur immunoassay systems from serum and plasma samples. Results are available in about 28 minutes.
April 2024—Sebia announced it has received FDA 510(k) clearance for its free light chain kappa and lambda assays, intended to aid in diagnosing and monitoring patients who have multiple myeloma and immunoglobulin light chain amyloidosis. The assays quantify kappa or lambda free light chains in human serum using an enzyme-linked immunosorbent assay procedure. The kits are for in vitro diagnostic use only.
April 2024—StatLab Medical Products announced the acquisition of Poly Scientific R&D, a manufacturer and supplier of pathology stains, reagents, and paraffin for anatomic pathology laboratories. The acquisition includes Histology Control Systems, a division of Poly Scientific that manufactures and supplies tissue control slides.
April 2024—Bio-Rad Laboratories has launched its online Quality Controls Learning Center, a free resource designed to provide laboratories with the educational resources needed to maintain quality control patient test results. The site provides a library of articles and best practices on quality control process and design, laboratory management, quality control data management, quality control troubleshooting and solutions, and the benefits of independent quality control.
April 2024—Sekisui Diagnostics has received emergency use authorization for its Osom Flu SARS-CoV-2 Combo test for use in professional and home testing settings. The lateral flow immunochromatographic assay is intended for the qualitative detection and differentiation of influenza A and B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen. The test is for in vitro diagnostic use.
March 2024—The Matrix Plus chemistry reference kit and standalone, ultra-high Matrix Plus level F for the calibration verification testing of creatinine assays by enzymatic and colorimetric methods are available from Verichem Laboratories. The ready-to-use reference materials offer constant protein content and pH across all concentration levels. The five-level Matrix Plus kit and level F feature a creatinine range from 0.2 mg/dL to 30.0 mg/dL and are intended to be treated as patient specimens. Shelf life and open-vial stability are 21 months from the manufacturing date.
March 2024—Bio-Rad Laboratories has published the third workbook in a P.A.C.E.-approved series designed to provide lab professionals with the training and education needed to maintain reliable test results. “Quality Control Process Optimization with Cost of Quality Application” focuses on a practical approach of cost of quality to the laboratory workflow process of quality control. After using the workbook, laboratorians will be able to construct a basis worksheet to calculate the failure costs of a selected failed laboratory process.
March 2024—Agilent Technologies announced an agreement with Incyte to develop companion diagnostics in hematology and oncology. The agreement enables Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development, global regulatory approvals, and commercialization to support clinical trials as well as the potential registration and commercialization of companion diagnostics in the United States and Europe.
